# Epics Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epics-therapeutics

- Industry: Biotechnology
- Headquarters: Belgium
- Website: www.epicstherapeutics.com
- Total disclosed funding: $8.5M
- Latest round: Seed (May 24, 2018)
- Investors on record: 5

## About

Founded in 2018 by Jean Combalbert and based in Belgium, Epics Therapeutics SA is a pharmaceutical discovery and development firm that develops small-molecule therapeutics that target RNA epigenetic pathways that contribute to cancer development. As of 2023, Franz Obermayr serves as the CEO of the company. In April 2018, Epic Therapeutics SA raised EUR 7.2 million in seed funding from S.R.I.W.

The company's pipeline includes products that target RNA epigenetic modifications, a field that complements the system-wide epigenetic regulation of physiological processes. The firm is developing treatments based on RNA epigenetic target modulators, with the goal of translating RNA modification routes into the discovery of first-in-class medications in oncology and other disorders.

Epics is also working to integrate its drug discovery and development platform and develop a robust pipeline of programs across the writer, eraser, and reader classes of RNA epigenetic targets to produce new medications for the treatment of human diseases.

## Funding rounds

- Seed, May 24, 2018, $8.5M — Société Régionale d'Investissement de Wallonie, Sambrinvest, Seido Capital, Newton Biocapital Partners, Investsud

## Investors

- Société Régionale d'Investissement de Wallonie — Seed
- Sambrinvest (https://capitalatlas.ai/funds/sambrinvest) — Seed
- Seido Capital (https://capitalatlas.ai/funds/seido-capital) — Seed
- Newton Biocapital Partners (https://capitalatlas.ai/funds/newton-biocapital-partners) — Seed
- Investsud — Seed